The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Biosynexus, Inc.

Adma Biologics, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Adma Biomanufacturing, LLC

University of Sheffield

Uniformed Services University of the Health Sciences, an Institution of Higher Learning Within the Department of Defense

Henry Jackson Foundation

James J Mond

Adam S Grossman

Andrew Lees

Jerrold B Grossman

Dov A Goldstein

Dennis M Klinman

Daniela Verthelyi

Ken Ishii

Clifford M Snapper

Scott Michael Walsh

Mayda Gursel

Xinle Cui

Mary Catherine Pittaway

Gerald Walter Fischer

Richard F Schuman

Jeffrey R Stinson

Anjali G Shah

Simon J Foster

Philip McDowell

Simon Clarke

John Fitzgerald Kokai-Kun

Julie M Adams

Tanya I Chanturiya

Joseph J Drabick

Kristy Brummel

S Dept Of Molecular Biology And Biotech Clarke

S Depof Molecular Biology And Biotech Foster

P Dept Of Molecular Biology And Biotech Mcdowell

K Dept Of Molecular Biology And Biotech Brummel

John F Kokai-Kun

Lioubov Grinberg

The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).

Compositions and methods for the treatment of immunodeficiency

The present invention relates to compositions and methods for the treatment of infection caused by. In particular, the invention provides human hyperimmune globulin and compositions thereof for preventing or treating pneumococcal infection. The invention provides methods of producing hyperimmune globulin containing high titers of opsonophagocytic anti-pneumococcal antibodies, compositions containing same, and methods of using the compositions for the prevention and treatment of pneumococcal infection. The invention further provides methods of preventing or treating pneumococcal infection (e.g., upper respiratory infections (e.g., bronchitis, otitis, sinusitis, etc.)) in immunocompromised subjects via administration of hyperimmune globulin compositions of the invention (e.g., containing a high titer of opsonophagocytic anti-pneumococcal antibodies) to immunocompromised subjects.

Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizing antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins. Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.

Multimeric fusion protein vaccine and immunotherapeutic

The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizmg antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins, Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.

The present disclosure provides modified human herpesvirus glycoprotein B (gB) proteins that incorporate unique mechanisms for generating proteins that mimic their native conformation to enhance their immunogenicity. The modified herpesvirus gB proteins insert a peptide linker at the furin cleavage site in the extracellular domain of herpesvirus gB. When expressed, the gB subunit associates in triplicate to produce a homotrimeric complex, mimicking the native conformation of the gB protein. Also provided are protein complexes comprising a homotrimeric complex of a modified herpesvirus gB protein and herpesvirus gH and gL proteins. Also provided are nucleic acids encoding the modified herpesvirus gB proteins, methods of inducing or suppressing an immune response in a subject by administering a vaccine comprising the modified herpesvirus gB protein, or nucleic acid encoding the same, or a protein complex comprising a homotrimeric complex of the modified herpesvirus gB protein and herpesvirus gH and gL proteins.

Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines

A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula:5' NNNT-CpG-WNNN3&#x2032;wherein the CpG motif is unmethylated, W is A or T, and N, N, N, N, N, and Nare nucleotides, or the formula:5&#x2032; RY-CpG-RY 3&#x2032;wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host. In some embodiments, the oligodeoxynucleotide includes the nucleic acid sequences set forth as SEQ ID NO: 137.

Oligodeoxynucleotide and its use to induce an immune response

Growing community of inventors

Silver Springs, MD, United States of America

James J Mond